Table 2.

AMPs in clinical or preclinical trials.

AMP	Template	Phase of Clinical Trials	Administration	Application	Reference
Iseganan	Protegrin-1	Phase 2/3	Topical	Prevention of ventilator-associated pneumonia	[231]
XF-73	Porphyrin	Phase 1	Nasal gel	Prevention of postoperative S. aureus colonization and infection	[232]
P-113	Histatin 5	Phase 2	Mouth rinse	Reduce gum bleeding, gingivitis and plaque	[233]
Omiganan	Indolicidin	Phase 2	Topical gel	Treatment of mild to moderate atopic dermatitis	[234]
LTX-109	Synthetic peptidomimetic	Phase 1/2	Topical	Prevention of nasal infections caused by methicillin-sensitive/resistant S. aureus	[235]
Onc72	Oncocin	Preclinical	Subcutaneous	Treatment of antibiotic-susceptible K. pneumoniae	[236]
OP-145	LL-37	Preclinical	Implant coating	Prevention of S. aureus-induced biomaterial-associated infections	[237]
Lactoferrin	Not applicable	Phase 4	Oral	Prevention of neonatal sepsis	[238]
Murepavadin	Protegrin-1	Phase 1	Intravenous	Treatment of pneumonia caused by P. aeruginosa infection	[239]
Surotomycin	Daptomycin	Phase 2	Oral	Treatment of C. difficile-associated infection	[240]
LL-37	Not applicable	Phase 2	Topical	Control of infection of diabetic foot ulcers	[241]